The top 100 stock
market authors
selected for publication
market authors
selected for publication
Keryx Biopharmaceuticals Inc. (KERX)
()
- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Articles
- Instablogs
- StockTalks
- Sentiment
- Comments
- News & PR
- Market Currents
- Buzz
- Twitter: KERX
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
Analysis - Latest Articles by most recent | most commented
- Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
- 6 More Stock Briefs
- Monday's Closing Update
- Cancer Stocks Hammered Once Again
- Keryx: Another Beneficiary of the ASCO Effect
- Stocks with 10x Gain Since March: Room to Run?
- Closing Update: Stocks End at Day's Highs, Advance Eight Days Out of Nine
- Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News
- 26 Bullish Breakout Stocks on Big Volume
- Cancer Stocks on the Go: Winners and Losers
- Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
- Cancer Stocks Plunge Following ASCO Meeting
- Closing Update for Monday, August 3
- Sulonex from Keryx: Unlikely Phase III Success
- The Best and Worst Performing Stocks in the U.S.
- Best and Worst Performing Stocks in the Russell 3,000 Year to Date
- Klarman, Witmer & Einhorn: Examining 2009 Q1 13F Filings
- Keryx Pharmaceuticals: Time to Buy Back In
- FDA Calendar Updates: Transcept Pharma Surges on Deal
- Keryx Biopharma Investors Should Wait for More News on Trials
- Cancer Stocks: Lagging Again
- Latest Peek Inside the Portfolios of Klarman, Witmer, Third Ave.
- Biotech Busy with Bevy of Small Deals
- Protalix BioTherapeutics: This Dream Could Take Time to Manifest
- Cancer Stocks Soar With Annual ASCO Meeting
- Closing Update for Tuesday, Sept. 29: Dow Fronts Narrow Losses
- FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results
- Keryx Pharma Could Turn into a Real Winner Down the Road
- Cancer Stocks Slide Again
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most active
Instabloggers.-
1
TraderMark
-
2
Don Dion
-
3
Cliff Wachtel
-
4
Mike Havrilla
-
5
James Quinn
Top Instabloggers » -
1
-
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
